CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria

CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria

Abstract Oral H1-antihistamines (AHs) are the most commonly used therapy to treat allergic rhinitis and chronic urticaria. Older, first-generation AHs (e.g. diphenhydramine, hydroxyzine) have significant and common side effects including sedation, impairment with decreased cognitive function, poor s...

Full description

Bibliographic Details
Main Authors: Michael N. Fein, David A. Fischer, Andrew W. O’Keefe, Gord L. Sussman
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Histamine
H1-antihistamines
Diphenhydramine
CSACI position statement
Online Access:http://link.springer.com/article/10.1186/s13223-019-0375-9

Internet

http://link.springer.com/article/10.1186/s13223-019-0375-9

Similar Items